CorVel quarterly revenues increase 13% to $91.5 million

CorVel Corporation (Nasdaq: CRVL) reported earnings per share of $0.64 for the quarter ended June 30, 2010, a 30% increase compared to $0.49 in the same quarter of the prior fiscal year.  The Company reported quarterly revenues of $91.5 million, a 13% increase compared to $81.3 million in the same quarter of the prior fiscal year.

Revenue growth compared to the same quarter the prior year was lead by a 31% increase in the Company's  Patient Management product line which includes traditional case management services and claims management.  Claims management growth included additional new customers and the improved integration of CorVel service components.  CorVel's claims management program continues to gain momentum in the market place.  The Company has increased its information technology resourcing in order to advance the pace of delivery of new features for clients.  CorVel seeks to improve claims outcomes through such investments.  These technology projects will incorporate artificial intelligence to improve the Company's managed workflow environment.  

Network Solutions revenue was flat compared to the same quarter last year.  Growth in the Company's  pharmacy solutions and directed care networks offset a slight decline in medical bill review revenues.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024